Agilent Secures First On-array Sequence Capture IP, But Market Impact is Unclear

Robert Schueren, vice president and general manager of its Agilent's genomics business, said the company is open to licensing its IP to others.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.